Cargando…

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age

BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for their ability to reduce disease activity, namely clinical relapses and signal changes on magnetic resonance imaging (MRI). Disease activity appears age dependent. Thus, the greatest benefit would be expected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yinan, Salter, Amber, Jin, Shan, Culpepper, William J., Cutter, Gary R., Wallin, Mitchell, Stuve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020738/ https://www.ncbi.nlm.nih.gov/pubmed/33868459 http://dx.doi.org/10.1177/17562864211006499

Ejemplares similares

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Clinical trials in multiple sclerosis: potential future trial designs
por: Manouchehri, Navid, et al.
Publicado: (2019)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region
por: Hittle, Michael, et al.
Publicado: (2023)

Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2022)

Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey
por: Rinker, John R, et al.
Publicado: (2015)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
por: Marrie, Ruth Ann, et al.
Publicado: (2014)

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

The role of the complement system in Multiple Sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis
por: Vasileiou, Eleni S., et al.
Publicado: (2022)

Severity and worsening of fatigue among individuals with multiple sclerosis
por: Salter, Amber, et al.
Publicado: (2023)

To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Tugemann, Bastian, et al.
Publicado: (2022)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Cognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature
por: Chiang, Hsueh-Sheng, et al.
Publicado: (2022)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Editorial: Animal models of multiple sclerosis: can they advance future therapies?
por: DeSilva, Tara Maria, et al.
Publicado: (2023)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
por: Negron, Austin, et al.
Publicado: (2020)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021)

National estimates of self-reported sitting time in adults with multiple sclerosis
por: Sasaki, JE, et al.
Publicado: (2018)

How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity
por: Kister, Ilya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n0j6ll9dhsnug4rb2knp5m8323